Nanotechnology in Ophthalmology

1st Edition - July 18, 2023
Imprint: Academic Press
Editors: Mahendra Rai, Marcelo Luis Occhiutto, Sushama Talegaonkar
Language: English
Paperback ISBN:
9 7 8 - 0 - 4 4 3 - 1 5 2 6 4 - 1
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 5 2 6 5 - 8

**Selected for Doody’s Core Titles® 2024 in Ophthalmology**Nanotechnology in Ophthalmology is a comprehensive and up-to-date reference on the role and applications of nanotech… Read more

Purchase options

BLOOM INTO SPRING SAVINGS

Save up to 25% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

**Selected for Doody’s Core Titles® 2024 in Ophthalmology**

Nanotechnology in Ophthalmology is a comprehensive and up-to-date reference on the role and applications of nanotechnology in ophthalmology, from drug delivery and treatment of ocular diseases to toxicity issues. Written by experts from the nanotechnology, ophthalmology, and pharmacology fields, this book has a unique, broad and diverse scope, including chapters on nanosensor-based diagnostic tools, delivery of nanobiomaterials, implantable materials and devices, delivery of nanobiomaterials, nanotechnology for medical and surgical treatment, regenerative medicine, and more. This book provides a valuable reference to researchers working in the areas of ophthalmology, nanoscience and pharmacology, and clinical fellows who are interested in nanoophthalmology as a reference for their practice and research.

Cover image
Title page
Table of Contents
Copyright
List of contributors
Foreword
Preface
Section I. General introduction
Chapter 1. Nanotechnology in the diagnosis of ocular diseases, drug delivery, and therapy: challenges and opportunities
1. Introduction
2. Nanotechnology for early diagnosis of ocular diseases
3. Conventional treatment modalities
4. Advantages and disadvantages of the conventional treatment
5. Challenges in ocular drug delivery
6. Ocular drug delivery and the role of nanotechnology
7. Different types of eye disease and how nanotechnology can counter them
8. Different types of nanoformulations are used as a carrier to treat various diseases
9. Role of phytoconstituents in the drug delivery system
10. Conclusion and future perspectives
Section II. Perspectives of nanotechnology in ocular drug delivery
Chapter 2. An overview of ocular drug delivery systems—conventional and novel drug delivery systems
1. Introduction
2. Ocular barriers to drug delivery
3. Conventional dosage forms
4. Nanotechnology-based approaches
5. Recent advancements in ocular drug delivery
6. Clinical status of nanotechnology-based ocular delivery systems
7. Patents on various ophthalmic preparations and devices
8. Commercialized conventional and novel ophthalmic formulations
9. Conclusion and future prospective
Chapter 3. Fathoming biopharmaceutical tenets and characterization techniques for the plausible ophthalmic drug delivery performance
1. Introduction
2. Topical drug delivery
3. Considerations for the optimal design
4. Nanotechnology-based drug delivery carriers
5. Characterization of ophthalmic drug forms
6. Conclusions
Section III. Biomedical applications of nanocarriers in ocular diseases, and toxicity
Chapter 4. Newer nanoformulated peptides in ocular therapeutics: issues and approaches
1. Introduction
2. Challenges related to peptide ocular delivery
3. Ocular bioavailability and peptide transport systems
4. Newer peptide therapeutics and their nanocarriers trending in ophthalmology
5. Conclusion and future perspective
Chapter 5. An overview of nanocarriers used in corneal disease
1. Introduction
2. Corneal anatomical and physiological factors
3. Effect of the tear film on drug permeability
4. Benefits and limitations of common ocular delivery routes
5. Nanomedicine
6. Future challenges and perspectives
7. Conclusion
Chapter 6. Nanomedicine-based solutions: nanoemulsions and nanosuspension for ocular diseases
1. Introduction
2. Nanomedicines for the management of ocular disease
3. Conclusion
Chapter 7. Nanotechnology for surgical glaucoma treatment
1. Introduction
2. The goal of glaucoma treatment
3. Nanoparticle-based formulations and wound-healing modulation
4. Glaucoma drainage devices and nanodevices
5. Nanotechnology-ocular devices for glaucoma treatment
6. Nanotechnology for optic nerve regeneration
7. Limitations of nanomaterials
8. Future perspectives and conclusions
Disclosure
Chapter 8. Nanotechnology in glaucoma—conceptual and clinical treatment aspects
1. Introduction
2. Limitations in current management of glaucoma
3. Nanotechnology and nanomedicine
4. Nanomedicine and drug delivery
5. Liposomes
6. Polymeric nanoparticles
7. Lipid nanoparticles
8. Dendrimers
9. Niosomes
10. Cyclodextrin
11. Challenges and looking ahead
12. Conclusion
Chapter 9. Polymeric and lipid nanocarriers in glaucoma
1. Introduction
2. Current treatment options for glaucoma
3. Ocular barriers and challenges in treatment with conventional dosage forms
4. Nanotechnology in glaucoma management
5. Polymeric nanocarriers in the management of glaucoma
6. Lipidic nanocarriers
7. Toxicity concerns
8. Regulatory aspects of nanoformulations
9. Conclusion
Chapter 10. Lipid-based nanotherapeutic interventions for the treatment of ocular diseases: current status and future perspectives
1. Introduction
2. Lipid-based nanotherapeutic interventions for the treatment of ocular diseases
3. Patented nanolipid carriers for ocular disorders
4. Marketed formulations of lipid-based nanotherapeutic interventions for the treatment of ocular diseases
5. Conclusion and perspectives
Chapter 11. Nanotechnology in retinal drug delivery
1. Introduction
2. Human eyeball and different barriers in drug delivery
3. Eye diseases
4. Traditional routes in retinal drug delivery
5. Nanotechnology in ocular drug delivery
6. Conclusion
7. Limitations and future perspectives
Chapter 12. Advances in nanotherapies in the management of microbial keratitis
1. Introduction
2. Classification of microbial keratitis
3. Nanotechnology in microbial keratitis
4. Conclusion and future prospects
Chapter 13. Polymeric micelles: a novel treatment option for mycotic keratitis
1. Introduction
2. Novel drug delivery systems for delivering drugs to the eyes with a special focus on polymeric micelles
3. Fundamental considerations of polymeric micelles for ocular delivery
4. Opportunities and challenges of using polymeric micelles to treat fungus keratitis
5. Conclusion
Chapter 14. Use of nanotechnology in dry eye syndrome
1. Introduction
2. Pathophysiology, causes, and diagnosis
3. Immune-based inflammation mechanisms in DED
4. Medical management of dry eye syndrome
5. Limitations in current treatment methods of dry eye syndrome
6. Nanotechnology in the management of dry eye syndrome
7. Current challenges and future prospects
Chapter 15. Advances in nanotechnology-based anti-VEGF agents for the management of ocular angiogenesis
1. Introduction
2. Neovascular disorders of the posterior segment of the eye
3. Available anti-VEGF drugs: features and challenges
4. Nanotechnological systems for anti-VEGF delivery for the treatment of ocular angiogenesis
5. Conclusion
Chapter 16. Application of nanotechnology towards reduction of oxidative stress-induced ocular diseases
1. Introduction
2. Oxidative stress and ocular diseases
3. Barriers to ocular drug delivery—anatomical and physiological
4. Synthetic and natural antioxidants targeting ROS in ocular diseases
5. Nanotechnology: a novel ocular drug delivery approach
6. Toxicity of nanodelivery system
7. Future perspectives
8. Conclusion
Chapter 17. Nanotechnology in age-related macular degeneration
1. Introduction
2. Treatment evolution and present-day options
3. Current challenges in AMD treatment
4. Nanotechnology in AMD
5. Conclusion and future perspectives
Chapter 18. Nanotechnological strategies for the treatment of diabetic retinopathy: progress and limitations
1. Introduction
2. Diabetic retinopathy
3. Nanocarriers for the ocular drug delivery: focusing on diabetic retinopathy
4. Conclusion
Chapter 19. Advanced hydrogel-based platform for ocular drug delivery
1. Introduction
2. Hydrogels
3. Hydrogel-based ocular drug delivery system
4. Current challenges and future prospects
5. Conclusion
Chapter 20. Nanotoxicity in ocular drug delivery
1. Introduction
2. Barriers to eye
3. Conventional methods to treat ophthalmic diseases
4. Advantages of nanomaterials in drug delivery
5. Nanotoxicity
6. Conclusion
Index

Mahendra Rai

Prof. Mahendra Rai is a UGC Basic Science Research Faculty Fellow and former Head of the Department of Biotechnology at Sant Gadge Baba Amravati University, India. He is currently a senior visiting professor in the Department of Chemistry at the Federal University of Piaui (UFPI), Brazil.

His areas of expertise include microbial biotechnology and nanobiotechnology, focusing on the green synthesis of metal nanoparticles using fungi and their applications as nanoantimicrobials against pathogenic microbes. His research is interdisciplinary, integrating microbial biotechnology with nanotechnology.

Professor Rai has received several prestigious awards, including the Father T.A. Mathias Award from the All India Association for Christian Higher Education and the Medini Award from the Government of India. He has participated in multiple international collaborations and has held visiting positions at various institutions, including the University of Geneva (Switzerland), Debrecen University (Hungary), and Nicolaus Copernicus University (Poland).

Affiliations and expertise

Senior Visiting Professor, Federal University of Piaui, Brazil

Marcelo Luis Occhiutto

Marcelo Occhiutto, MD, is a Physician in the Department of Anterior Segment and Refractive Surgery of the Tadeu Cvintal Institute of Ophthalmology, Brazil. He is also a Researcher at the Department of Ophthalmology and Human Genetics in the University of Campinas. His most recent research focuses on the use of nanotechnology for antiproliferative drugs in glaucoma surgeries and the identification of genetic polymorphisms that participate in the etiology of this serious eye disease.

Affiliations and expertise

Physician, Department of Anterior Segment and Refractive Surgery, Tadeu Cvintal Institute of Ophthalmology, São Paulo, Brazil Researcher, University of Campinas, São Paulo, Brazil

Sushama Talegaonkar

Dr. Sushama Talegaonkar is an Associate Professor at the Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, India. She has approximately 21 years of experience, and has published more than 220 research papers in high impact international journals. Besides this, she has coauthored 6 books and authored 15 chapters in international reference books. Recently, she received the Professor C. J. Shishoo Award for Best Research. Her research paper titled “Development and bioavailability assessment of ramipril nanoemulsion formulation” has received the most cited research paper award on behalf of Elsevier and the board of European Journal of Pharmaceutics and Biopharmaceutics. She was awarded the prestigious Motan Devi Dandiya Biennial Prize for best publication in Pharmaceutical Sciences for the period 2010–11. Dr. Talegaonkar is actively involved in developing a wide variety of smart and functionalized nanodrug delivery systems for targeted anticancer drug delivery.

Affiliations and expertise

Associate Professor, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Nanotechnology in Ophthalmology

Purchase options

BLOOM INTO SPRING SAVINGS

Institutional subscription on ScienceDirect

Mahendra Rai

Marcelo Luis Occhiutto

Sushama Talegaonkar

Related books